Harvard Study Links Epstein-Barr Virus to MS Mechanism, Showing 2.5-Fold Higher Viral Levels
Updated
Updated · The Boston Globe · Jul 15
Harvard Study Links Epstein-Barr Virus to MS Mechanism, Showing 2.5-Fold Higher Viral Levels
3 articles · Updated · The Boston Globe · Jul 15
Summary
Science Translational Medicine published Harvard-led findings that untreated multiple sclerosis patients show about twice the EBV-driven CD4 T-cell response of healthy volunteers, outlining how the virus may trigger the autoimmune attack.
Blood and saliva samples from patients in Boston, Baltimore and Bergen showed EBV levels were 2.5-fold higher in MS patients, supporting the idea that infected B-cells help misdirect immune cells against brain and spinal cord tissue.
Anti-CD20 therapies drove those immune-cell levels nearly back to normal and left patients with almost no detectable EBV in saliva, offering a possible explanation for why some of the most effective MS drugs work so well.
The results build on a 2022 Harvard study that found EBV raises MS risk 32-fold and could steer development of vaccines or antivirals that target the virus instead of relying on lifelong immune suppression.
MS affects about 1 million people in the US and 3 million worldwide; more than 95% of adults carry EBV, suggesting disease risk depends less on infection alone than on how the immune system responds.
A common virus triggers MS. With vaccine trial results due this year, could we soon prevent this devastating neurological disease?
If a virus fuels multiple sclerosis, will future treatments target the infection instead of suppressing the entire immune system?
Unraveling the 32-Fold MS Risk: How Epstein-Barr Virus Drives Multiple Sclerosis and the Race for Targeted Prevention
Overview
A major breakthrough in Multiple Sclerosis (MS) research was announced in July 2026, revealing how the Epstein-Barr virus (EBV) triggers the immune response that leads to MS. Scientists have identified specific EBV antigens involved in the disease process, marking a pivotal step for drug development. This detailed understanding offers a clearer roadmap for creating targeted therapies that address the root cause of MS, rather than just managing symptoms. The findings open new possibilities for more precise treatments and guide future research towards innovative approaches for MS prevention and care.